Zevra Therapeutics (ZVRA) Accumulated Expenses: 2014-2024
- Zevra Therapeutics' Accumulated Expenses fell 42.59% to $6.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.1 million, marking a year-over-year decrease of 42.59%. This contributed to the annual value of $6.1 million for FY2024, which is 42.59% down from last year.
- As of Q4 2024, Zevra Therapeutics' Accumulated Expenses stood at $6.1 million, which was down 42.59% from $10.7 million recorded in Q4 2023.
- In the past 5 years, Zevra Therapeutics' Accumulated Expenses registered a high of $10.7 million during Q4 2023, and its lowest value of $1.1 million during Q4 2021.
- For the 3-year period, Zevra Therapeutics' Accumulated Expenses averaged around $6.2 million, with its median value being $6.1 million (2024).
- As far as peak fluctuations go, Zevra Therapeutics' Accumulated Expenses soared by 537.84% in 2023, and later slumped by 42.59% in 2024.
- Quarterly analysis of 5 years shows Zevra Therapeutics' Accumulated Expenses stood at $1.3 million in 2020, then declined by 18.86% to $1.1 million in 2021, then surged by 58.73% to $1.7 million in 2022, then surged by 537.84% to $10.7 million in 2023, then crashed by 42.59% to $6.1 million in 2024.
- Its last three reported values are $6.1 million in Q4 2024, $10.7 million for Q4 2023, and $1.7 million during Q4 2022.
